e-drug
[Top] [All Lists]

[e-drug] India refuses to hike cancer drug price

E-DRUG: India refuses to hike cancer drug price
-----------------------------------------------

[To learn more about compulsory licensing under TRIPS, read this FAQ of the 
World Trade Organization. 
http://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm (fix URL in 
browser if broken). India is free to determine whether a compulsory licence is 
required or not and has followed all steps under TRIPS i.e. tried to negotiate 
a voluntary licence with the licence holder and arranged for the licence holder 
to be paid a royalty.  - Moderator]

India refuses to hike cancer drug price
THE HINDU, 12th July 2012
NARAYAN LAKSHMAN
http://www.thehindu.com/news/national/article3632391.ece


Over the summer one thing about U.S. President Barack Obama has become clear. 
His hawkishness in foreign policy affects not only nations like Pakistan and 
Yemen, which are saddled with U.S. drones carrying out targeted assassinations 
on their soil. India too is very much a victim of Mr. Obama�s harshest policy 
campaigns, albeit in a less headline-grabbing area: cancer medication pricing.

In a hearing on Capitol Hill that slipped under the radar of media scrutiny, a 
top Obama administration official blatantly pressed the case for the deployment 
of American lobbying power to keep the price of cancer drug Nexavar closer to 
the $5,000-per-month-mark that it now sells at in India.

In doing so, Deputy Director of the U.S. Patent and Trademark Office (PTO), 
Teresa Rea, was equally pushing for Congressional approval for the Obama White 
House�s strong-arm tactics to bully Indian manufacturers of Nexavar�s generic 
equivalent into giving up their plan to sell their product at a much more 
affordable $157 per month.

An insightful Huffington Post investigative report on the covert campaign by 
the PTO argued that during the 70-minute hearing, Ms. Rea �repeatedly 
castigated India's government for approving the generic drug, calling the move 
an egregious violation of World Trade Organisation treaties.�� According to 
reports Ms. Rea said that she was �dismayed and surprised,�� by India�s 
decision and admitted to �personally�� engaging �various agencies of the Indian 
government�� in efforts to knock it down.

It is hard to miss the contrast between Mr. Obama�s domestic policies to keep 
drug prices low via the Supreme-Court-validated Affordable Care Act and his 
administration�s persistent efforts to protect drug firm revenues even in 
developing nations such as India, which have a toxic combination of poverty and 
rampant disease.

A principal stakeholder that would appear to be deriving vast profits under the 
aegis of the U.S. President�s protection is none other than pharmaceuticals 
giant Bayer AG. Despite the Germany-based company�s best lobbying efforts the 
Government of India has refused to bow to U.S. pressure and �continues to offer 
the generic alternative, which was approved in March after several months of 
negotiations with [the company],�� according to the investigative study.

Following India�s decision not to yield to the clout of the deep-pocketed 
Bayer, whose earnings touched $3.4 billion last year, Indian pharmaceutical 
Natco Pharma obtained permission to sell the generic drug and pay a royalty of 
six per cent on the revenue derived to Bayer. This arrangement is a widely 
accepted trade practice called �compulsory licensing,�� and is supported by WTO 
treaties, �an effort to ensure that good health care is not merely a privilege 
for the rich,�� and a process that is ironically used by the U.S. to address 
domestic drug shortages, the HuffPost report noted.

After her acerbic performance before Congress was criticised on the grounds 
that compulsory licensing was consistent with the WTO, Ms. Rea in a blog post 
reluctantly agreed that it �can be permissible under the TRIPS Agreement.��
Yet apparently adamant on blocking India�s efforts to make essential drugs 
affordable to the vast majority of its poor, she added that the U.S. was 
�trying to stop the granting of further compulsory licenses.

-- 
Dr Gopal Dabade,
57, Tejaswinagar,
Dharwad 580 002
Tel 0836-2461722
Cell (0)9448862270
www.jagruti.org
http://aidanindia.wordpress.com/
www.daf-k.cjb.net
<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] India refuses to hike cancer drug price, Dr Gopal Dabade <=